Coya Therapeutics COYA
Coya Therapeutics reported a net loss of $10.62 million for the three months ended Sep 30, 2026.
Coya Therapeutics (COYA) filed a 10-Q with the SEC on Nov 10, 2026, 8:10 am ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-454478
- Revenue: $234,134 for the three months ended Sep 30, 2026
- Net loss: $10.62 million for the three months ended Sep 30, 2026
- Cash and equivalents: $35.8 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning is new
“Accordingly, substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that such financial statements are issued.”
First warning: the prior 10-Q (filed Aug 11, 2026) had no going-concern warning. Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
1 new risk factor
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $234K | $244K | −3.9% |
| Operating income and margin | −$10.95M · -4676.2% | −$7.05M · -2891.1% | −55%, margin −1785.1 pts |
| Net income | −$10.62M | −$6.64M | −60% |
| Operating cash flow | −$7.24M | −$7.38M | +1.9% |
| Cash | $35.8M | $43.18M | −17% |
New risk factors (1)
- We are a clinical stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future, which raises substantial doubt about our ability to continue as a going concern. +2 more paragraphs